The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Subscribe To Our Newsletter & Stay Updated
